Next-generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
Details
Publication Year 2023-08,Volume 4,Issue #3,Page 876-881
Journal Title
eJHaem
Publication Type
Research article
Abstract
Eltrombopag has been previously shown to be effective in reversing azacitidine-mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with intermediate- to high-risk myelodysplastic syndromes and thrombocytopenia. The results did not support a clinical benefit for the addition of eltrombopag to azacitidine. We investigated if the somatic mutational profiles in the patient cohort were associated with treatment outcomes. Based on the available data, we observed no imbalance in the mutational profiles between treatment arms or a clear association between identified somatic mutations and clinical outcomes.
Publisher
Wiley
Keywords
Ngs; azacitidine; myelodysplastic syndromes; thrombocytopenia; thrombopoietin receptor agonist
Department(s)
Clinical Haematology
PubMed ID
37601870
Open Access at Publisher's Site
https://doi.org/10.1002/jha2.694
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-11-08 07:27:58
Last Modified: 2023-11-08 07:28:27

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙